title: Omacetaxine Mepesuccinate for Chronic Myeloid Leukemia.
abstract: Omacetaxine mepesuccinate is approved by the Food and Drug Administration in the United States for the treatment of chronic myeloid leukemia in chronic or accelerated phase resistant to two or more tyrosine kinase inhibitors. This review summarizes the mode of action, pharmacokinetics, efficacy and safety of omacetaxine mepesuccinate. Omacetaxine mepesuccinate has activity in chronic myeloid leukemia, especially in the chronic phase, regardless of the presence of ABL1 kinase domain mutations. Omacetaxine mepesuccinate has distinct but manageable adverse events profile. Omacetaxine mepesuccinate is a treatment option for a subset of patients with refractory chronic myeloid leukemia.
authors: a Department of Hematology and Medical Oncology , the Winship Cancer Institute of Emory University, Emory University School of Medicine , Atlanta , GA , USA.
authors: Yasmin
authors: Y
authors: Rosshandler
authors: a Department of Hematology and Medical Oncology , the Winship Cancer Institute of Emory University, Emory University School of Medicine , Atlanta , GA , USA.
authors: Ann Q
authors: AQ
authors: Shen
authors: b Department of Leukemia , the University of Texas M.D. Anderson Cancer Center , Houston , TX , USA.
authors: Jorge
authors: J
authors: Cortes
authors: a Department of Hematology and Medical Oncology , the Winship Cancer Institute of Emory University, Emory University School of Medicine , Atlanta , GA , USA.
authors: Hanna Jean
authors: HJ
authors: Khoury
mesh_terms: D020533:Angiogenesis Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D000972:Antineoplastic Agents, Phytogenic / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D001752:Blast Crisis / Q000188:drug therapy; D003062:Codon; D016044:Fusion Proteins, bcr-abl / Q000037:antagonists & inhibitors / Q000235:genetics; D006248:Harringtonines / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D000077863:Homoharringtonine; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics; D015465:Leukemia, Myeloid, Accelerated Phase / Q000188:drug therapy; D015466:Leukemia, Myeloid, Chronic-Phase / Q000188:drug therapy; D009154:Mutation; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors; D000972:Antineoplastic Agents, Phytogenic; C581634:BCR-ABL1 fusion protein, human; D003062:Codon; D006248:Harringtonines; D000077863:Homoharringtonine; D016044:Fusion Proteins, bcr-abl
keywords: Chronic myeloid leukemia; omacetaxine mepesuccinate; tyrosine kinase inhibitor